Abstract: Poster Presentations |


Esra Uzaslan, MD*; Funda N. Coskun, MD; Dane Ediger, MD; Erkan Rodoplu, MD; Mehmet Karadag, MD; Ercument Ege, MD; Oktay Gozu, MD
Author and Funding Information

Uludag University Medical Faculty Chest Disease Department, Bursa, Turkey


Chest. 2005;128(4_MeetingAbstracts):245S. doi:10.1378/chest.128.4_MeetingAbstracts.245S-b
Text Size: A A A
Published online


PURPOSE:  The aim of this study to evaluate the of post-treatment effects of Leukotriene Receptor Antagonists (LTRA) in persistent asthmatic patients who have been treated with inhaler steroid and LTRA, by investigating clinical and laboratory parameters before addition of LTRA, end of treatment with LTRA and at least three months after ending of LTRA treatment.

METHODS:  We retrospectively investigated clinical data of 19 asthmatic patients (16 females, 3 males, mean age 33.3±2.5 years) before LTRA treatment,last day of LTRA treatment and at least three months after ending of LTRA treatment and compared symptom score, medication score (number of controller drugs for asthma), total dose of inhaler steroid and lung function tests of patients for each visits.

RESULTS:  We found decreases in symptom score (p<0.01), medication score (p>0.05), total dose of inhaler steroid (p>0.05),and increases lung function tests (p>0.05) at the end of the treatment.When we evaluated same parameters at least three months after the ending of LTRA treament, we observed continuation of increases in FEV1 and PEF values (p>0.05) comparing to beginning and ending of treatment and also a significant decrease in total dose of inhaler steroid comparing to beginning of treatment (p<0.05).

CONCLUSION:  We come to the conclusion that in persistent asthmatic who use LTRA in addition to inhaler steroids,the improvement in lung function tests, symptom scores and medication scores are protected and the total dose of inhaler steroids needed for control of asthma is decreased,even 3 months after the ending of treatment.

CLINICAL IMPLICATIONS:  The post-treatment effects of LTRA continues three months after the discontinuation of the treatment in asthmatics.

DISCLOSURE:  Esra Uzaslan, None.BaselinePost-treatment3 months laterSymptom score1.3±0.80.5±0.60.9±0.8Medication score1.4±0.91.2±0.71.3±0.2Inhaled steroid dose (mcg)875±583695±391445±216FEV1 (L)2.62±0.92.66±0.92.75±0.8PEF (L/sec)5.68±1.76.27±1.86.77±1.8

Wednesday, November 2, 2005

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543